Ligand-Based Design on the Dog-Bone-Shaped BIBR1532 Pharmacophoric Features and Synthesis of Novel Analogues as Promising Telomerase Inhibitors with in Vitro and in Vivo Evaluations

Ahmed A. Al-Karmalawy, Mohamed S. Nafie, Moataz A. Shaldam, Ayman Abo Elmaaty, Samar A. Antar, Anwar A. El-Hamaky, Mohamed A. Saleh, Ahmed Elkamhawy, Haytham O. Tawfik

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

Telomerase is an outstanding biological target for cancer treatment. BIBR1532 is a non-nucleoside selective telomerase inhibitor; however, it experiences ineligible pharmacokinetics. Herein, we aimed to design new BIBR1532-based analogues as promising telomerase inhibitors. Therefore, two novel series of pyridazine-linked to cyclopenta[b]thiophene (8a-f) and tetrahydro-1-benzothiophene (9a-f) were synthesized. A quantitative real-time polymerase chain reaction was utilized to investigate the telomerase inhibitory activity of candidates. Notably, 8e and 9e exhibited the best inhibition profiles. Moreover, 8e showed strong antitumor effects against both MCF-7 and A549 cancer cell lines. The effects of 8e on the cell cycle and apoptosis were measured. Besides, 8e was evaluated for its in vivo antitumor activity using solid Ehrlich carcinoma. The reduction in both the tumor weight and volume was greater than doxorubicin. Also, molecular docking and ADME studies were performed. Finally, a SAR study was conducted to gain further insights into the different telomerase inhibition potentials upon variable structural modifications.

Original languageEnglish
Pages (from-to)777-792
Number of pages16
JournalJournal of Medicinal Chemistry
Volume66
Issue number1
DOIs
StatePublished - 12 Jan 2023

Fingerprint

Dive into the research topics of 'Ligand-Based Design on the Dog-Bone-Shaped BIBR1532 Pharmacophoric Features and Synthesis of Novel Analogues as Promising Telomerase Inhibitors with in Vitro and in Vivo Evaluations'. Together they form a unique fingerprint.

Cite this